BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37478397)

  • 1. Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches.
    Lou PJ; Jacky Lam WK; Hsu WL; Pfeiffer RM; Yu KJ; Chan CML; Lee VCT; Chen TC; Terng SD; Tsou YA; Leu YS; Liao LJ; Chang YL; Chien YC; Wang CP; Lin CY; Hua CH; Lee JC; Yang TL; Hsiao CH; Wu MS; Tsai MH; Cheng HC; Hildesheim A; Chen CJ; Chan KCA; Liu Z;
    J Clin Oncol; 2023 Sep; 41(26):4257-4266. PubMed ID: 37478397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs.
    Chen GH; Liu Z; Yu KJ; Coghill AE; Chen XX; Xie SH; Lin DF; Huang QH; Lu YQ; Ling W; Lin CY; Lu ZJ; Fan YY; Tang LQ; Sampson JN; Li H; King AD; Middeldorp JM; Hildesheim A; Cao SM
    Clin Chem; 2022 Jul; 68(7):953-962. PubMed ID: 35325087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
    Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions.
    Lam WKJ; King AD; Miller JA; Liu Z; Yu KJ; Chua MLK; Ma BBY; Chen MY; Pinsky BA; Lou PJ; Woo JKS; Hsu WL; Simon J; Doolan DL; Waterboer T; Hui EP; Li H; Tsang RK; Wong KCW; Goh JP; Vlantis AC; Ai QY; Wong LM; Abdullah V; Lin JC; Chen CJ; Pfeiffer RM; Le QT; Lee AWM; Ji M; Cao S; Ma J; Chan ATC; Chan KCA; Hildesheim A
    J Natl Cancer Inst; 2023 Apr; 115(4):355-364. PubMed ID: 36723440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.
    Simon J; Brenner N; Reich S; Langseth H; Hansen BT; Ursin G; Ferreiro-Iglesias A; Brennan P; Kreimer AR; Johansson M; Pring M; Nygard M; Waterboer T
    Cancer Epidemiol; 2022 Apr; 77():102117. PubMed ID: 35121404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
    Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
    Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epstein-Barr virus (Herpesviridae:
    Smirnova KV; Lubenskaya AK; Senyuta NB; Dushenkina TE; Gurtsevitch VE
    Vopr Virusol; 2023 Sep; 68(4):291-301. PubMed ID: 38156586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma.
    Tan LP; Tan GW; Sivanesan VM; Goh SL; Ng XJ; Lim CS; Kim WR; Mohidin TBBM; Mohd Dali NS; Ong SH; Wong CY; Sawali H; Yap YY; Hassan F; Pua KC; Koay CE; Ng CC; Khoo AS;
    Int J Cancer; 2020 Apr; 146(8):2336-2347. PubMed ID: 31469434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
    Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
    Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
    [No Abstract]   [Full Text] [Related]  

  • 16. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
    Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
    Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
    Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
    Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
    Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
    Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.